Please assess the completion status of the following clinical trial:

Trial Title: A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed Informed Consent Form~* Age ≥ 18 years~* Documented ovarian, primary peritoneal, or fallopian tube carcinoma that has recurred~* No prior chemotherapy in the recurrent setting~* Measurable disease~* Recovered from prior radiation therapy or surgery~Exclusion Criteria:~* Prior chemotherapy treatment for recurrent ovarian, primary peritoneal, or fallopian tube carcinoma~* History of abdominal fistula, gastrointestinal perforation (GIP), or intra-abdominal abscess~* Patients with clinical symptoms or signs of gastrointestinal (GI) obstruction or who require parenteral hydration, parenteral nutrition, or tube feeding~* Patients with evidence of abdominal free air not explained by paracentesis or recent surgical procedure~* Current, recent, or planned participation in an experimental drug study~* History of systemic bevacizumab (Avastin) or other vascular endothelial growth factor (VEGF) or VEGF receptor-targeted agent use~* Inadequately controlled hypertension~* Prior history of hypertensive crisis or hypertensive encephalopathy~* New York Heart Association Class II or greater congestive heart failure (CHF)~* History of myocardial infarction or unstable angina~* History of stroke or transient ischemic attack (TIA)~* Known central nervous system (CNS) disease except for treated brain metastasis~* Significant vascular disease or recent peripheral arterial thrombosis~* History of hemoptysis~* Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Carboplatin and gemcitabine + bevacizumab (Type: EXPERIMENTAL): Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m\^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Bevacizumab 15 mg/kg was administered IV on Day 1 of each of the six 21-day treatment cycles. The bevacizumab dose was based on the patient's weight at baseline and remained the same throughout the study.
- Carboplatin and gemcitabine + placebo (Type: ACTIVE_COMPARATOR): Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m\^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Placebo was administered by IV on Day 1 of each of the six 21-day treatment cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).